BRIEF—Novartis gene therapies VP joins Poseida

Cell and gene therapy company Poseida Therapeutics has recruited Brent Warner from Swiss pharma giant Novartis.

Mr Warner has joined the US company as president, Gene Therapy, bringing with him more than 15 years of biotech and pharmaceutical experience, most recently serving as vice president, Gene Therapy and Rare Disease at Novartis. Prior roles included serving as a US commercial leader in hemophilia A at BioMarin Pharmaceutical and a variety of strategic operational roles at Biogen.

Mark Gergen, chief executive of Poseida, said that Mr Warner brings “a strong track record of leadership in gene therapy and rare genetic diseases to Poseida”.

“Alongside our top scientists, he will lead the execution of drug development programs in gene therapy, including our recent research collaboration with Takeda,” Mr Gergen said.